Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,137,463
  • Shares Outstanding, K 62,875
  • Annual Sales, $ 306,980 K
  • Annual Income, $ -251,580 K
  • 60-Month Beta 1.48
  • Price/Sales 10.17
  • Price/Cash Flow N/A
  • Price/Book 5.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.24
  • Number of Estimates 4
  • High Estimate -0.95
  • Low Estimate -1.52
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -87.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.65 +16.19%
on 05/11/20
53.62 -5.43%
on 04/30/20
-2.83 (-5.29%)
since 04/29/20
3-Month
30.79 +64.68%
on 03/17/20
57.06 -11.13%
on 03/05/20
-4.13 (-7.53%)
since 02/28/20
52-Week
30.79 +64.68%
on 03/17/20
59.89 -15.33%
on 02/19/20
+10.52 (+26.18%)
since 05/29/19

Most Recent Stories

More News
PTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in...

PTCT : 50.71 (+1.62%)
PTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the...

PTCT : 50.71 (+1.62%)
Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

PFE : 38.19 (+0.03%)
SRPT : 152.27 (-0.48%)
PTCT : 50.71 (+1.62%)
SLDB : 2.95 (-2.64%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 shares of its common stock and...

PTCT : 50.71 (+1.62%)
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.

PTCT : 50.71 (+1.62%)
BSGM : 9.38 (-5.16%)
PTC Therapeutics to Acquire Censa Pharmaceuticals

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development...

PTCT : 50.71 (+1.62%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present in a virtual format at the following conferences:

PTCT : 50.71 (+1.62%)
PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -55.17% and -13.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PTCT : 50.71 (+1.62%)
PTC Therapeutics: 1Q Earnings Snapshot

SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $112.7 million in its first quarter.

PTCT : 50.71 (+1.62%)
PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending .

PTCT : 50.71 (+1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PTCT with:

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

2nd Resistance Point 51.99
1st Resistance Point 51.35
Last Price 50.71
1st Support Level 49.49
2nd Support Level 48.28

See More

52-Week High 59.89
Last Price 50.71
Fibonacci 61.8% 48.77
Fibonacci 50% 45.34
Fibonacci 38.2% 41.91
52-Week Low 30.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar